Article
A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib.
PloS one - 1 Jan 2013
Augis Vanessa, Airiau Kelly, Josselin Marina, Turcq Béatrice, Mahon François-Xavier, Belloc Francis
Abstract excerpt
PURPOSE: BIM is essential for the response to tyrosine-kinase inhibitors (TKI) in chronic myeloid leukaemia (CML) patients. Recently, a deletion polymorphism in intron 2 of the BIM gene was demonstrated to confer an intrinsic TKI resistance in Asian patients. The present study aimed at identifying mutations in the BIM sequence that could lead to imatinib resistance independently of BCR-ABL mutations. EXPERIMENTAL...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.